Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Talquetamab outcomes from practice outside of clinical trials: The bital study

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMario ArnaoJPJosé María Sánchez PinaMPMiriam Concepcion Gonzalez Pardo

Discussion

Loading...

Member takes

Overview

Retrospective study finds high overall response rate and favorable survival in relapsed refractory multiple myeloma, suggesting the promise of real-world data.

Key Points

  • This research aims to evaluate the effectiveness and safety of talquetamab in patients with triple-class exposed relapsed refractory multiple myeloma.
  • Ongoing retrospective, noninterventional study across 68 sites in Spain
  • Data collected from patient medical records, including demographics, disease characteristics, and therapy history
  • Assessment of treatment outcomes based on response rates, progression-free survival, and overall survival
  • Overall response rate of 83.8% in patients treated with talquetamab
  • Median overall survival of 26.2 months observed in the study
  • Reported side effects included skin reactions and infections, consistent with existing data

Cite This Study

Arnao et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d16ehttps://doi.org/10.1182/blood-2025-5827
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs2025
  2. 2Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  3. 3Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials2025 · 1 citations
  4. 4Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  5. 5Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025